Boston Scientific's Watchman heart implant shows improved safety profile in preliminary results

March 9, 2013 by Arezu Sarvestani

Boston Scientific hopes to reassure FDA regulators about the safety and efficacy of its Watchman stroke prevention implant with results from its PREVAIL study, the presentation for which was pulled from the lineup at the American College of Cardiology conference in San Francisco today.

Boston Scientific's Watchman device illustration

Boston Scientific (NYSE:BSX) today unveiled new results from a clinical trial of its Watchman stroke prevention device, reporting that the cardiac implant met 2 of 3 co-primary endpoints for safety and effectiveness compared with drug therapy.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.